BPC-157 vs Retatrutide
Extensively Studied vs Extensively Studied
compatible Safe combination; BPC-157 may provide GI protective benefits during retatrutide use.
Molecular Data
BPC-157 Retatrutide
Weight 1,419.53 Da 4,731.33 Da
Half-life <30 minutes ~6 days
Chain 15 amino acids 39 amino acids
Type Pentadecapeptide Triple GLP-1/GIP/glucagon agonist
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
BPC-157 Retatrutide
Status Extensively Studied Extensively Studied
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.